human follicle stimulating hormone with HCG C-terminal peptide

a long-acting recombinant FSH like substance, consisting of the human FSH alpha-subunit and a hybrid beta-subunit that is composed of the human FSH beta-subunit and the C-terminus part (CTP) of the human HCG beta-subunit

Also Known As:

Networked: 30 relevant articles (0 outcomes, 7 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Stegmann, Barbara J: 6 articles (01/2022 - 07/2015)
2.	Griesinger, Georg: 4 articles (01/2018 - 04/2012)
3.	Devroey, Paul: 4 articles (01/2016 - 10/2010)
4.	Mannaerts, Bernadette: 4 articles (07/2015 - 10/2010)
5.	Chen, Shee-Uan: 3 articles (11/2021 - 01/2018)
6.	McCrary Sisk, Christine: 3 articles (03/2017 - 01/2016)
7.	Gordon, Keith: 3 articles (07/2016 - 07/2015)
8.	Devroey, P: 3 articles (12/2009 - 12/2004)
9.	Behre, Hermann M: 2 articles (01/2022 - 03/2017)
10.	Guan, Yanfen: 2 articles (01/2022 - 03/2017)

Related Diseases

1.	Body Weight (Weight, Body) 01/01/2016 - "The aim of the present study was to characterize the pharmacokinetic profile of corifollitropin alfa and examine the relationships between dose, intrinsic factors [body weight, body mass index (BMI), age and race] and corifollitropin alfa pharmacokinetics. " 07/01/2010 - "Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women." 12/01/2009 - "The study population comprised 1506 treated patients with mean age of 31.5 years and body weight of 68.6 kg. Ongoing pregnancy rates of 38.9% for the corifollitropin alfa group and 38.1% for rFSH were achieved, with an estimated non-significant difference of 0.9% [95% confidence interval (CI): -3.9; 5.7] in favor of corifollitropin alfa. " 01/01/2017 - "Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35-42 years with a body weight ≥50 kg: a randomized controlled trial." 07/01/2016 - "Women with regular menstrual cycles aged 18-36 and body weight >60 kg (Engage) or ≤60 kg (Ensure), or women aged 35-42 years and body weight ≥50 kg (Pursue), received a single injection (100 µg or 150 µg) of corifollitropin alfa (based on body weight and age) or daily rFSH. "
2.	Ovarian Hyperstimulation Syndrome 04/01/2012 - "In three studies of corifollitropin alfa treatment, we assessed all cases of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication of ovarian stimulation treatment. " 08/01/2011 - "In large, pooled analyses of clinical trials, the incidence of ovarian hyperstimulation syndrome in both the corifollitropin alfa and rFSH treatment arms was consistent with that expected in the relatively young patient population. " 07/01/2015 - "The incidence of serious adverse events was 0.4% versus 2.7% in the corifollitropin alfa and recombinant FSH groups, respectively, and of ovarian hyperstimulation syndrome (OHSS; all grades) was 1.7% in both groups. " 04/01/2012 - "Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH." 09/01/2010 - "Finally, corifollitropin alfa is well tolerated and is not correlated with serious adverse events, except for the slightly higher incidence of ovarian hyperstimulation syndrome compared with traditional management with recombinant FSH."
3.	Infertility (Sterility) 03/07/2017 - "Corifollitropin alfa is a long-acting FSH-analog with demonstrated action in women seeking infertility care. " 04/01/2009 - "Thus, corifollitropin alfa has the potential to serve as a viable fertility agent and to gain a place in the infertility market." 12/22/2022 - "The study involved 111 women with infertility and PCOS, who were offered different methods of pre-pregnancy pre-treatment prior to undergoing controlled ovarian stimulation according to a short protocol with recombinant gonadotropin corifollitropin alfa (Elonva®). " 04/01/2009 - "Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility." 04/01/2009 - "Corifollitropin alfa is being developed by Schering-Plough Corp as an injectable, long-acting follicle-stimulating hormone (FSH) agonist for the treatment of infertility. "
4.	Hypersensitivity (Allergy) 08/01/2011 - "In this multicentre, phase III uncontrolled trial, patients (>60 kg) started treatment with one injection of 150 µg corifollitropin alfa on cycle Day 2 or 3 of menses and 0.25 mg ganielix on stimulation Day 5 or 6. Primary outcome measures were antibody formation against corifollitropin alfa (using highly sensitive radioimmunoprecipitation assay), hypersensitivity reactions, local tolerance and adverse events (AEs). "
5.	Female Infertility 01/01/2012 - "Corifollitropin alfa for female infertility." 08/01/2011 - "Corifollitropin alfa: a new option to treat female infertility." 08/01/2001 - "Furthermore, the pharmacokinetic and dynamic profile of FSH-CTP may lead to the development of new, more convenient regimens for the treatment of male and female infertility."

Related Drugs and Biologics

1.	Hormones (Hormone)
2.	Gonadotropins
3.	Gonadotropin-Releasing Hormone (GnRH)
4.	Follicle Stimulating Hormone (Follitropin)
5.	follitropin beta
6.	Peptides (Polypeptides)
7.	Chorionic Gonadotropin (Human Chorionic Gonadotropin)
8.	Antral
9.	N- acetyl- (4- chlorophenylalanyl)(1)- (4- chlorophenylalanyl)(2)- tryptophyl(3)- arginyl(6)- alanine(10)- LHRH

Related Therapies and Procedures

1.	Injections